Table 1.
Baseline demographics of the treatment group
| Gender (n = 170) | Female | 74 (44%) |
| Male | 96 (56%) | |
| Age (Median [IQR]) | 65.5 [56.0–73.0] | |
| Race (n = 170) | American Indian or Alaska Native | 0 (0%) |
| Asian | 3 (2%) | |
| Black or African American | 16 (9%) | |
| Native Hawaiian or Pacific Islander | 1 (1%) | |
| White or Caucasian | 140 (82%) | |
| Unknown | 7 (4%) | |
| Other | 3 (2%) | |
| Ethnicity (n = 170) | Hispanic or Latino | 19 (11%) |
| Non-Hispanic | 137 (81%) | |
| Unknown | 14 (8%) | |
| Other | 0 (0%) | |
| Enrollment Year (n = 170) | 2015 | 7 (4%) |
| 2016 | 37 (22%) | |
| 2017 | 68 (40%) | |
| 2018 | 26 (15%) | |
| 2019 | 23 (14%) | |
| 2020 | 9 (5%) | |
| ECOG (n = 164) | 0 | 78 (48%) |
| 1 | 61 (37%) | |
| 2 or more | 25 (15%) | |
| Grade (n = 81) | Well Differentiated | 57 (70%) |
| Moderately Differentiated | 12 (15%) | |
| Poorly Differentiated | 12 (15%) | |
| Tumor Site (n = 152) | Foregut | 39 (26%) |
| Midgut | 54 (36%) | |
| Pancreas | 36 (24%) | |
| Hindgut | 10 (7%) | |
| Unknown | 13 (9%) | |
| Tumor Burden % (Median [IQR]) | 25.9 [11.9–49.8] | |
| Tumor Location (n = 165) | Bilobar | 77 (47%) |
| Unilobar | 88 (53%) | |
| Extrahepatic Metastasis (n = 161) | ||
| Yes (n = 77, 48%) | Lung | 22 (29%) |
| Lymph Nodes | 22 (29%) | |
| Bone | 14 (18%) | |
| Peritoneum | 9 (12%) | |
| Small Bowel | 6 (8%) | |
| Brain | 1 (1%) | |
| Gastric | 1 (1%) | |
| Large Bowel | 1 (1%) | |
| Prostate | 1 (1%) | |
| Uterus | 1 (1%) | |
| Other | 28 (36%) | |
| No (n = 85, 52%) | ||
| Hepatic Resection | Yes | 23 (14%) |
| Systemic Therapy (n = 144) | Octreotide | 119 (83%) |
| Biologic | 49 (34%) | |
| Cytotoxic | 58 (40%) | |
| Arterial Embolization (n = 166) | Yes | 62 (37%) |
| No | 104 (63%) | |
| Biliary Intervention (n = 15) | Metallic Stent | 2 (13%) |
| Plastic Stent | 1 (7%) | |
| Percutaneous Biliary Drainage | 1 (7%) | |
| Surgical Anastomosis | 5 (31%) | |
| Other | 7 (47%) | |
| Ascites | 10 (6%) | |
| Baseline Laboratories | Bilirubin in mg/dL (Median [IQR]) | 0.9 [0.6–1.4] |
| Albumin in g/dL (Median [IQR]) | 4.1 [3.8–4.3] | |
| ALT in u/L (Median [IQR]) | 42.0 [23.8–73.0] | |
| AST in u/L (Median [IQR]) | 52.0 [28.0–72.0] | |
| INR Ratio (Median [IQR]) | 1.1 [1.0–1.3] | |
| Creatinine in mg/dL (Median [IQR]) | 1.1 [0.9–1.4] | |
| Chromogranin A in ng/mL (Median [IQR]) | 543 [215–2981] | |
| Platelet Count in thousands/uL (Median [IQR]) | 239.5 [170.5–315.8] | |
IQR interquartile range